DE69029884T2 - 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten - Google Patents

5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten

Info

Publication number
DE69029884T2
DE69029884T2 DE69029884T DE69029884T DE69029884T2 DE 69029884 T2 DE69029884 T2 DE 69029884T2 DE 69029884 T DE69029884 T DE 69029884T DE 69029884 T DE69029884 T DE 69029884T DE 69029884 T2 DE69029884 T2 DE 69029884T2
Authority
DE
Germany
Prior art keywords
carbon atoms
group
represent
bromine
chlorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69029884T
Other languages
German (de)
English (en)
Other versions
DE69029884D1 (de
Inventor
Laura Smith Lang
Stella M Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69029884D1 publication Critical patent/DE69029884D1/de
Publication of DE69029884T2 publication Critical patent/DE69029884T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69029884T 1989-08-18 1990-08-16 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten Expired - Fee Related DE69029884T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39586089A 1989-08-18 1989-08-18

Publications (2)

Publication Number Publication Date
DE69029884D1 DE69029884D1 (de) 1997-03-20
DE69029884T2 true DE69029884T2 (de) 1997-08-14

Family

ID=23564835

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69029884T Expired - Fee Related DE69029884T2 (de) 1989-08-18 1990-08-16 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten

Country Status (15)

Country Link
EP (1) EP0413329B1 (enExample)
JP (1) JP3131693B2 (enExample)
KR (1) KR100192745B1 (enExample)
AT (1) ATE148628T1 (enExample)
AU (1) AU633346B2 (enExample)
CA (1) CA2023560C (enExample)
DD (1) DD297328A5 (enExample)
DE (1) DE69029884T2 (enExample)
DK (1) DK0413329T3 (enExample)
ES (1) ES2099700T3 (enExample)
HU (1) HU215959B (enExample)
IE (1) IE902978A1 (enExample)
IL (1) IL95412A (enExample)
TW (1) TW287948B (enExample)
ZA (1) ZA906544B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0538783B1 (de) * 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
TW314467B (enExample) * 1993-03-31 1997-09-01 Hoechst Ag
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
DE102006017896A1 (de) † 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
JP6629840B2 (ja) * 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
AU2019232153B2 (en) 2018-03-09 2023-07-13 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
KR20230140410A (ko) * 2022-03-25 2023-10-06 바스테라 주식회사 3-페닐이속사졸 유도체 및 이를 유효성분으로 함유하는 안질환 예방 또는 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JPH0390024A (ja) 1991-04-16
DK0413329T3 (da) 1997-08-18
JP3131693B2 (ja) 2001-02-05
CA2023560C (en) 2000-12-12
KR100192745B1 (ko) 1999-06-15
IL95412A0 (en) 1991-06-30
HU215959B (hu) 1999-03-29
ES2099700T3 (es) 1997-06-01
TW287948B (enExample) 1996-10-11
DD297328A5 (de) 1992-01-09
ZA906544B (en) 1991-06-26
KR910004193A (ko) 1991-03-28
IE902978A1 (en) 1991-02-27
AU633346B2 (en) 1993-01-28
CA2023560A1 (en) 1991-02-19
ATE148628T1 (de) 1997-02-15
EP0413329A2 (en) 1991-02-20
EP0413329B1 (en) 1997-02-05
DE69029884D1 (de) 1997-03-20
AU6110490A (en) 1991-02-21
HU905064D0 (en) 1991-01-28
HUT59600A (en) 1992-06-29
IL95412A (en) 1996-01-31
EP0413329A3 (en) 1992-04-15

Similar Documents

Publication Publication Date Title
DE69207847T2 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
DE69019774T2 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
DE69807281T2 (de) Difluprednat enthaltende Zusammensetzungen
DE3872029T2 (de) Rektal absorbierbare form von l-dopa.
DE69425334T2 (de) 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
EP0413329B1 (en) 5-Methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
DE69224071T2 (de) Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
US5677335A (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular disease
DE69921008T2 (de) Behandlung von Rückenmarkverletzungenbedingter Impotenz
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69424183T2 (de) 6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
CH646057A5 (de) Mittel zur behandlung von glaucoma.
DE69819900T2 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
DE69005974T2 (de) Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69229688T2 (de) Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten
JP3527256B2 (ja) 抗アレルギー点眼剤
DE69518706T2 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
DE69026016T2 (de) Verwendung von 2-Cycloalkylamino-Oxazolinen zur Senkung oder Stabilisierung des intraokulären Druckes
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE3012837A1 (de) Analgetische und myotonolytische praeparate
EP0170237B1 (en) Use of 5-(3 ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione for the preparation of an ophthalmic topical agent
DE69710258T2 (de) Mittel zur Beschleunigung des Tränenflusses enthaltend einen Serotonin-Liganden, insbesondere Aminoalkoxybibenzyle
DE69600714T2 (de) Antiallergische Zusammensetzung enthaltend eine Phosphorsäurediester-Verbindung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee